Robert Seifert1,2,3,4, Katharina Kessel1, Katrin Schlack3,5, Manuel Weber2,3,4, Ken Herrmann2,3,4, Maximilian Spanke2,3,4, Wolfgang P Fendler2,3,4, Boris Hadaschik3,4,6, Jens Kleesiek4,7, Michael Schäfers1,3, Matthias Weckesser1,3, Martin Boegemann3,5, Kambiz Rahbar8,9. 1. Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149, Münster, Germany. 2. Department of Nuclear Medicine, University Hospital Essen, Essen, Germany. 3. West German Cancer Center (WTZ), Münster and Essen, Germany. 4. German Cancer Consortium (DKTK), Essen, Germany. 5. Department of Urology, University Hospital Münster, Münster, Germany. 6. Department of Urology, University Hospital Essen, Essen, Germany. 7. Division of Radiology, German Cancer Research Center, Heidelberg, Germany. 8. Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149, Münster, Germany. rahbar@uni-muenster.de. 9. West German Cancer Center (WTZ), Münster and Essen, Germany. rahbar@uni-muenster.de.
Abstract
INTRODUCTION: [177Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging treatment option for patients with end-stage prostate cancer. However, response to Lu-PSMA therapy is only achieved in approximately half of patients. It is clinically important to identify patients at risk of poor outcome. Therefore, the aim of this study was to evaluate pretherapeutic PSMA PET derived total tumor volume and related metrics as prognosticators of overall survival in patients receiving Lu-PSMA therapy. METHODS: A total number of 110 patients form the Departments of Nuclear Medicine Münster and Essen were included in this retrospective analysis. Baseline PSMA PET-CT was available for all patients. Employing a previously published approach, all tumor lesions were semi-automatically delineated in PSMA PET-CT acquisitions. Total lesion number, total tumor volume (PSMA-TV), total lesion uptake (PSMA-TLU = PSMA-TV * SUVmean), and total lesion quotient (PSMA-TLQ = PSMA-TV / SUVmean) were quantified for each patient. Log2 transformation was used for regressions. RESULTS: Lesion number, PSMA-TV, and PSMA-TLQ were prognosticators of overall survival (HR = 1.255, p = 0.009; HR = 1.299, p = 0.005; HR = 1.326, p = 0.002). In a stepwise backward Cox regression including lesion number, PSMA-TV, PSA, LDH, and PSMA-TLQ, only the latter two remained independent and statistically significant negative prognosticators of overall survival (HR = 1.632, p = 0.011; HR = 1.239, p = 0.024). PSMA-TLQ and LDH were significant negative prognosticators in multivariate Cox regression in contrast to PSA value. CONCLUSION: PSMA-TV was a statistically significant negative prognosticator of overall survival in patients receiving Lu-PSMA therapy. PSMA-TLQ was an independent and superior prognosticator of overall survival compared with PSMA-TV.
INTRODUCTION: [177Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging treatment option for patients with end-stage prostate cancer. However, response to Lu-PSMA therapy is only achieved in approximately half of patients. It is clinically important to identify patients at risk of poor outcome. Therefore, the aim of this study was to evaluate pretherapeutic PSMA PET derived total tumor volume and related metrics as prognosticators of overall survival in patients receiving Lu-PSMA therapy. METHODS: A total number of 110 patients form the Departments of Nuclear Medicine Münster and Essen were included in this retrospective analysis. Baseline PSMA PET-CT was available for all patients. Employing a previously published approach, all tumor lesions were semi-automatically delineated in PSMA PET-CT acquisitions. Total lesion number, total tumor volume (PSMA-TV), total lesion uptake (PSMA-TLU = PSMA-TV * SUVmean), and total lesion quotient (PSMA-TLQ = PSMA-TV / SUVmean) were quantified for each patient. Log2 transformation was used for regressions. RESULTS: Lesion number, PSMA-TV, and PSMA-TLQ were prognosticators of overall survival (HR = 1.255, p = 0.009; HR = 1.299, p = 0.005; HR = 1.326, p = 0.002). In a stepwise backward Cox regression including lesion number, PSMA-TV, PSA, LDH, and PSMA-TLQ, only the latter two remained independent and statistically significant negative prognosticators of overall survival (HR = 1.632, p = 0.011; HR = 1.239, p = 0.024). PSMA-TLQ and LDH were significant negative prognosticators in multivariate Cox regression in contrast to PSA value. CONCLUSION:PSMA-TV was a statistically significant negative prognosticator of overall survival in patients receiving Lu-PSMA therapy. PSMA-TLQ was an independent and superior prognosticator of overall survival compared with PSMA-TV.
Entities:
Keywords:
Lu-PSMA; PET-CT; PSMA; Total tumor volume; mCRPC
Authors: Hojjat Ahmadzadehfar; Kambiz Rahbar; Stefan Kürpig; Martin Bögemann; Michael Claesener; Elisabeth Eppard; Florian Gärtner; Sebastian Rogenhofer; Michael Schäfers; Markus Essler Journal: EJNMMI Res Date: 2015-06-20 Impact factor: 3.138
Authors: Jake Kendrick; Roslyn J Francis; Ghulam Mubashar Hassan; Pejman Rowshanfarzad; Jeremy S L Ong; Martin A Ebert Journal: Eur J Nucl Med Mol Imaging Date: 2022-08-17 Impact factor: 10.057
Authors: Kerstin Michalski; Claudius Klein; Tonio Brueggemann; Philipp T Meyer; Cordula Annette Jilg; Juri Ruf Journal: J Nucl Med Date: 2021-03-31 Impact factor: 11.082
Authors: Finn Edler von Eyben; Glenn Bauman; Rie von Eyben; Kambiz Rahbar; Cigdem Soydal; Alexander R Haug; Irene Virgolini; Harshad Kulkarni; Richard Baum; Giovanni Paganelli Journal: Int J Mol Sci Date: 2020-11-28 Impact factor: 5.923
Authors: Thomas S C Ng; Xin Gao; Keyan Salari; Dimitar V Zlatev; Pedram Heidari; Sophia C Kamran Journal: Front Oncol Date: 2021-07-28 Impact factor: 6.244
Authors: Lena M Mittlmeier; Matthias Brendel; Leonie Beyer; Nathalie L Albert; Andrei Todica; Mathias J Zacherl; Vera Wenter; Annika Herlemann; Alexander Kretschmer; Stephan T Ledderose; Nina-Sophie Schmidt-Hegemann; Wolfgang G Kunz; Jens Ricke; Peter Bartenstein; Harun Ilhan; Marcus Unterrainer Journal: Front Oncol Date: 2021-05-21 Impact factor: 6.244
Authors: Robert Seifert; Katharina Kessel; Katrin Schlack; Matthias Weckesser; David Kersting; Konstantin E Seitzer; Manuel Weber; Martin Bögemann; Kambiz Rahbar Journal: Theranostics Date: 2021-07-13 Impact factor: 11.556